Ionis looks to Akcea for speedy launch of inotersen

With an eye toward a commercialization race in hereditary transthyretin (TTR) amyloidosis (hATTR), Ionis Pharmaceuticals Inc. (NASDAQ:IONS) granted its majority-owned subsidiary Akcea Therapeutics Inc. (NASDAQ:AKCA) rights to inotersen on Thursday. While Ionis said on a conference call that many suitors were interested in the antisense candidate, including large pharmas and smaller rare disease companies, the company told BioCentury it believed Akcea would be able to launch the

Read the full 678 word article

User Sign In